dalteparin has been researched along with Syndrome in 75 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Syndrome: A characteristic symptom complex.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated coagulation activity in relation to gender in patients with acute coronary syndromes and in healthy individuals of similar age, and related coagulation activity to levels of Xa inhibition during dalteparin treatment." | 9.13 | Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. ( Johnston, N; Oldgren, J; Siegbahn, A, 2008) |
| "The OASIS-5 trial was a double-blind, randomized comparison of fondaparinux and enoxaparin in 20,078 patients with acute coronary syndrome." | 9.12 | Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Fox, KA; Granger, CB; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2007) |
| "Patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) benefit from the early administration of aspirin, a small molecule glycoprotein IIb/IIIa inhibitor such as eptifibatide, and heparin." | 9.12 | Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin ( Armstrong, PW; Fitchett, DH; Goodman, SG; Langer, A; Mendelsohn, A; Tan, M, 2006) |
| "Switching from enoxaparin to bivalirudin for patients with ACS undergoing PCI appears to be clinically safe without increased risk of major bleeding complications, regardless of the time of enoxaparin administration, and is safe enough to warrant testing it in larger numbers." | 9.12 | Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. ( Kent, KM; Okubagzi, P; Satler, LF; Suddath, WO; Torguson, RL; Waksman, R; Wolfram, RM; Xue, Z, 2006) |
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 9.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| "In this dose-finding study, we sought to compare fondaparinux with enoxaparin in patients with acute coronary syndromes (ACS)." | 9.11 | A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. ( Bobbink, IW; Boland, J; Gardien, M; Klootwijk, P; Lensing, AW; Ruzyllo, W; Simoons, ML; Umans, VA; Vahanian, A; Van De Werf, F; Zeymer, U, 2004) |
| "Effects of thienopyridines ticlopidine (TIC) and clopidogrel (CL) on hemostasis in patients (pts) with non-ST-elevation acute coronary syndromes (NSTEACS) have not been compared." | 9.11 | [Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. ( Averkov, OV; Gratsianskiĭ, NA; Slavina, NN, 2005) |
| "The rate of death, myocardial infarction, and urgent revascularization at days 8 and 43 after randomization was compared among patients who received aspirin within the week before randomization with those who did not receive aspirin in the TIMI 11B trial." | 9.09 | Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. ( Antman, EM; Bozovich, GE; Gurfinkel, EP; Marcos, E; Mautner, B; McCabe, CH; Santopinto, J; Torres, V, 2001) |
| "Fifty-five patients with non-Q-wave myocardial infarction were randomized to receive double-blind treatment with tirofiban (0." | 9.09 | Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. ( Borzak, S; Cohen, M; Deckelbaum, LI; Diodati, JG; Harris, KE; Huynh, T; Laramée, P; Lo, MW; Sax, FL; Squire, IB; Théroux, P; Thornton, AR; Weber, S; White, HD, 1999) |
| "This randomized, double blind, placebo-controlled pilot trial evaluated the effect of dalteparin as an adjuvant to thrombolysis in patients with acute myocardial infarction regarding early reperfusion, recurrent ischemia and patency at 24 h." | 9.09 | Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). ( Ahlberg, G; Frostfeldt, G; Gustafsson, G; Helmius, G; Lindahl, B; Nygren, A; Siegbahn, A; Swahn, E; Venge, P; Wallentin, L, 1999) |
| " dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH." | 6.70 | Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 5.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "We evaluated coagulation activity in relation to gender in patients with acute coronary syndromes and in healthy individuals of similar age, and related coagulation activity to levels of Xa inhibition during dalteparin treatment." | 5.13 | Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. ( Johnston, N; Oldgren, J; Siegbahn, A, 2008) |
| "Patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE ACS) benefit from the early administration of aspirin, a small molecule glycoprotein IIb/IIIa inhibitor such as eptifibatide, and heparin." | 5.12 | Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin ( Armstrong, PW; Fitchett, DH; Goodman, SG; Langer, A; Mendelsohn, A; Tan, M, 2006) |
| "The goal of this study was to evaluate glycoprotein IIb/IIIa inhibition with eptifibatide when administered with indirect thrombin inhibition as compared with monotherapy with direct thrombin inhibition with bivalirudin among patients with non-ST-segment elevation acute coronary syndromes (ACS)." | 5.12 | A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. ( Braunwald, E; Bulle, T; Cohen, DJ; Fish, P; Gibson, CM; Jennings, LK; Kovach, R; Lakkis, N; Lui, HH; McCabe, CH; Morrow, DA; Murphy, SA; Palabrica, TM; Stone, PH, 2006) |
| "Switching from enoxaparin to bivalirudin for patients with ACS undergoing PCI appears to be clinically safe without increased risk of major bleeding complications, regardless of the time of enoxaparin administration, and is safe enough to warrant testing it in larger numbers." | 5.12 | Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial. ( Kent, KM; Okubagzi, P; Satler, LF; Suddath, WO; Torguson, RL; Waksman, R; Wolfram, RM; Xue, Z, 2006) |
| "A recent randomized, controlled trial, the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS 5) trial, reported that major bleeding was 2-fold less frequent with fondaparinux than with enoxaparin in acute coronary syndromes (ACS)." | 5.12 | Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Fox, KA; Mehta, SR; Moccetti, T; Piegas, LS; Theroux, P; Valentin, V; Wallentin, L; Yusuf, S, 2007) |
| "The OASIS-5 trial was a double-blind, randomized comparison of fondaparinux and enoxaparin in 20,078 patients with acute coronary syndrome." | 5.12 | Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. ( Afzal, R; Bassand, JP; Budaj, A; Chrolavicius, S; Eikelboom, JW; Faxon, DP; Fox, KA; Granger, CB; Mehta, SR; Peters, RJ; Wallentin, L; Yusuf, S, 2007) |
| "To study efficacy of treating patients with acute coronary syndrome (ACS) without ST segment elevation (STSE) with platelet dysaggregation drugs (aspirin, cardiomagnil, clopidogrel)." | 5.11 | [Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome]. ( Kapilevich, NA; Kisteneva, IV; Markov, VA; Novitskiĭ, VV; Poponina, TM, 2004) |
| "In this dose-finding study, we sought to compare fondaparinux with enoxaparin in patients with acute coronary syndromes (ACS)." | 5.11 | A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. ( Bobbink, IW; Boland, J; Gardien, M; Klootwijk, P; Lensing, AW; Ruzyllo, W; Simoons, ML; Umans, VA; Vahanian, A; Van De Werf, F; Zeymer, U, 2004) |
| "Effects of thienopyridines ticlopidine (TIC) and clopidogrel (CL) on hemostasis in patients (pts) with non-ST-elevation acute coronary syndromes (NSTEACS) have not been compared." | 5.11 | [Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome]. ( Averkov, OV; Gratsianskiĭ, NA; Slavina, NN, 2005) |
| "The rate of death, myocardial infarction, and urgent revascularization at days 8 and 43 after randomization was compared among patients who received aspirin within the week before randomization with those who did not receive aspirin in the TIMI 11B trial." | 5.09 | Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin. ( Antman, EM; Bozovich, GE; Gurfinkel, EP; Marcos, E; Mautner, B; McCabe, CH; Santopinto, J; Torres, V, 2001) |
| "Fifty-five patients with non-Q-wave myocardial infarction were randomized to receive double-blind treatment with tirofiban (0." | 5.09 | Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. ( Borzak, S; Cohen, M; Deckelbaum, LI; Diodati, JG; Harris, KE; Huynh, T; Laramée, P; Lo, MW; Sax, FL; Squire, IB; Théroux, P; Thornton, AR; Weber, S; White, HD, 1999) |
| "This randomized, double blind, placebo-controlled pilot trial evaluated the effect of dalteparin as an adjuvant to thrombolysis in patients with acute myocardial infarction regarding early reperfusion, recurrent ischemia and patency at 24 h." | 5.09 | Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). ( Ahlberg, G; Frostfeldt, G; Gustafsson, G; Helmius, G; Lindahl, B; Nygren, A; Siegbahn, A; Swahn, E; Venge, P; Wallentin, L, 1999) |
| "The FRISC II study addressed two key questions in the management of acute coronary syndromes: is it beneficial to extend low-molecular-weight heparin (LMWH) therapy with dalteparin beyond the initial period of acute treatment; and, is a strategy of early invasive therapy, including angioplasty and surgical revascularization, preferable to a more conservative strategy? The study focused on patients with unstable coronary artery disease (UCAD), that is, angina and non-ST-segment-elevation myocardial infarction (MI)." | 5.09 | Improving outcomes in acute coronary syndromes--the FRISC II trial. ( Kontny, F, 2001) |
| "On the basis of this methodology, enoxaparin would appear to be more effective than placebo when added to aspirin in acute coronary syndromes." | 4.81 | Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control. ( Cruickshank, MK; Massel, D, 2002) |
| " In early trials, such as FRISC (Fragmin during instability in coronary artery disease) and FRIC (Fragmin in unstable coronary artery disease), the results of extended treatment were inconclusive; however, the trial populations included patients of relatively low risk and used a once-daily dosing regimen." | 3.79 | Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease. ( Husted, S; Kher, A, 2000) |
| "The current standard of care for patients with non-ST-segment elevation acute coronary syndromes (ACS) includes antithrombotic therapy with aspirin and heparin." | 3.71 | Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. ( Antman, EM; Ball, SP; Becker, RC; Gibson, M; Murphy, SA; Rush, JE; Sanderink, G; Spencer, FA, 2002) |
| " dalteparin is associated with a low risk of major side effects and is as safe as the combination of abciximab and UFH." | 2.70 | Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. ( Armstrong, P; Califf, R; Husted, S; James, S; Kontny, F; Niemminen, M; Pfisterer, M; Simoons, ML; Wallentin, L, 2002) |
| "Lemierre's syndrome is a potentially fatal disease that usually presents with oropharyngeal infection, followed by sepsis, thrombosis of the internal jugular vein and septic emboli." | 2.45 | Unusual presentation of Lemierre's syndrome: two cases and a review. ( Brandjes, DP; Gerdes, VE; Soesan, M; van Gorp, EC; van Wissen, M, 2009) |
| "Lemierre's syndrome is characterized by acute oropharyngeal infection complicated by internal jugular venous thrombosis secondary to septic thrombophlebitis, and metastatic abscesses." | 2.43 | Lemierre's syndrome presenting with peritonsillar abscess and VIth cranial nerve palsy. ( Jones, C; O'Reilly, BJ; Seymour, FK; Siva, TM, 2006) |
| " They are more predictable in action, do not require frequent activated partial thromboplastin time (aPTT) measurements and dosage adjustments, are easier to administer, and are potentially more efficacious." | 2.41 | Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction. ( Monrad, ES, 2000) |
| "Currently, prospective clinical trials investigate the efficacy of combined use of LMWH with thrombolytics, GPIIb/IIIa blockers and the optimal dosage of LMWH during coronary interventions." | 2.41 | [Low molecular weight heparins in acute coronary syndrome]. ( Huber, K; Niessner, A; Niessner, H, 2001) |
| "We present three cases who developed deep vein thrombosis (DVT) and subsequent pulmonary thromboembolism (PTE) after transatlantic air travel." | 1.35 | Air travel and pulmonary embolism: "economy class syndrome". ( Arora, P; Bhatia, V; Kaul, U; Mittal, A; Pandey, AK; Parida, AK, 2009) |
| " Our case report suggests that antithrombotic treatment by targeting of the activated platelets with a potent platelet inhibitor during the acute phase of type II HIT syndrome followed by long-term administration of oral anticoagulation may be an additional, safe and effective therapeutic alternative that merits to be systematically studied." | 1.33 | Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome. ( Alexandridou, S; Betsis, D; Blouhos, K; Megalopoulos, A; Tsachalis, T; Tsalis, K; Vasiliadis, K, 2006) |
| "Unfractionated heparin (UFH) has been considered the standard anticoagulant for patients with non-ST-segment-elevation acute coronary syndromes (NSTE ACS), yet it has limitations, including an unpredictable dose-response and intravenous administration." | 1.33 | Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial. ( Goodman, S, 2005) |
| "To describe dosing practices and to identify risk factors for bleeding in patients with an acute coronary syndrome (ACS) who received treatment with enoxaparin." | 1.32 | Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. ( Douketis, JD; Forbes, L; Foster, GA; Macie, C, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (12.00) | 18.2507 |
| 2000's | 64 (85.33) | 29.6817 |
| 2010's | 2 (2.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van Wissen, M | 1 |
| Gerdes, VE | 1 |
| van Gorp, EC | 1 |
| Brandjes, DP | 1 |
| Soesan, M | 1 |
| Poponina, TM | 1 |
| Kapilevich, NA | 1 |
| Kisteneva, IV | 1 |
| Markov, VA | 1 |
| Novitskiĭ, VV | 1 |
| Kaul, S | 1 |
| Shah, PK | 1 |
| Goldmann, BU | 1 |
| Hamm, CW | 1 |
| Huber, K | 1 |
| Niessner, A | 1 |
| Niessner, H | 1 |
| Briassoulis, G | 1 |
| Fitrolaki, MD | 1 |
| Spanaki, AM | 1 |
| Gill-Schuster, D | 1 |
| Bergold, M | 1 |
| Holzer, L | 1 |
| Mooney, T | 1 |
| Joseph, P | 1 |
| Bhatia, V | 1 |
| Arora, P | 1 |
| Parida, AK | 1 |
| Mittal, A | 1 |
| Pandey, AK | 1 |
| Kaul, U | 1 |
| Jones, HU | 1 |
| Muhlestein, JB | 1 |
| Jones, KW | 1 |
| Bair, TL | 1 |
| Lavasani, F | 1 |
| Sohrevardi, M | 1 |
| Horne, BD | 1 |
| Doty, D | 1 |
| Lappe, DL | 1 |
| Gratsianskiĭ, NA | 3 |
| Levine, GN | 1 |
| Ferguson, JJ | 5 |
| Antman, EM | 5 |
| Bates, ER | 2 |
| Cohen, M | 6 |
| Every, NR | 1 |
| Harrington, RA | 2 |
| Pepine, CJ | 1 |
| Theroux, P | 3 |
| Averkov, OV | 2 |
| Slavina, NN | 2 |
| Dobrovol'skiĭ, AB | 1 |
| Grines, CL | 1 |
| O'Neill, W | 1 |
| Lee, DS | 1 |
| Bhatt, DL | 1 |
| Moliterno, DJ | 1 |
| Peacock, WF | 1 |
| Ellis, SG | 1 |
| Topol, EJ | 2 |
| Hermiller, JB | 1 |
| Macie, C | 1 |
| Forbes, L | 1 |
| Foster, GA | 1 |
| Douketis, JD | 1 |
| Simoons, ML | 2 |
| Bobbink, IW | 1 |
| Boland, J | 1 |
| Gardien, M | 1 |
| Klootwijk, P | 1 |
| Lensing, AW | 1 |
| Ruzyllo, W | 1 |
| Umans, VA | 1 |
| Vahanian, A | 1 |
| Van De Werf, F | 1 |
| Zeymer, U | 1 |
| Steg, PG | 2 |
| Juliard, JM | 1 |
| Galla, JM | 1 |
| Mahaffey, KW | 4 |
| Rokos, IC | 1 |
| Goodman, S | 1 |
| Califf, RM | 2 |
| Petersen, JL | 2 |
| Hasselblad, V | 1 |
| Katsouras, C | 1 |
| Michalis, LK | 1 |
| Papamichael, N | 1 |
| Adamides, K | 1 |
| Naka, KK | 1 |
| Nikas, D | 1 |
| Goudevenos, JA | 1 |
| Sideris, DA | 1 |
| Buckmaster, ND | 1 |
| Heazlewood, V | 1 |
| Scott, IA | 1 |
| Jones, M | 1 |
| Haerer, W | 1 |
| Hillier, K | 1 |
| Fitchett, DH | 1 |
| Langer, A | 3 |
| Armstrong, PW | 2 |
| Tan, M | 3 |
| Mendelsohn, A | 2 |
| Goodman, SG | 4 |
| Bozovich, GE | 2 |
| Dos Santos, A | 1 |
| Gurfinkel, EP | 2 |
| Gibson, CM | 1 |
| Morrow, DA | 1 |
| Murphy, SA | 2 |
| Palabrica, TM | 1 |
| Jennings, LK | 1 |
| Stone, PH | 1 |
| Lui, HH | 1 |
| Bulle, T | 1 |
| Lakkis, N | 1 |
| Kovach, R | 1 |
| Cohen, DJ | 1 |
| Fish, P | 1 |
| McCabe, CH | 3 |
| Braunwald, E | 2 |
| Waksman, R | 1 |
| Wolfram, RM | 1 |
| Torguson, RL | 1 |
| Okubagzi, P | 1 |
| Xue, Z | 1 |
| Suddath, WO | 1 |
| Satler, LF | 1 |
| Kent, KM | 1 |
| White, HD | 2 |
| Kleiman, NS | 1 |
| Lokhnygina, Y | 1 |
| Pieper, KS | 1 |
| Chiswell, K | 1 |
| Chew, DP | 1 |
| Berdan, LG | 1 |
| Aylward, PE | 1 |
| Nessel, CC | 1 |
| Jolly, S | 1 |
| Fitchett, D | 1 |
| Kukla, P | 1 |
| Bryniarski, L | 1 |
| Korpak-Wysocka, R | 1 |
| Bartuś, S | 1 |
| Giszterowicz, D | 1 |
| Dobrowolski, W | 1 |
| Dudek, D | 1 |
| Oliveira, GB | 1 |
| Avezum, A | 1 |
| Anderson, FA | 1 |
| Budaj, A | 2 |
| Dabbous, OH | 1 |
| Goldberg, RJ | 1 |
| Brieger, D | 2 |
| Fox, KA | 3 |
| Gore, JM | 1 |
| Granger, CB | 3 |
| Cardoso, R | 1 |
| Gonçalo, M | 1 |
| Tellechea, O | 1 |
| Maia, R | 1 |
| Borges, C | 1 |
| Silva, JA | 1 |
| Figueiredo, A | 1 |
| Fazel, R | 1 |
| Froehlich, JB | 1 |
| Williams, DM | 1 |
| Saint, S | 1 |
| Nallamothu, BK | 1 |
| Bassand, JP | 2 |
| Mehta, SR | 2 |
| Wallentin, L | 8 |
| Piegas, LS | 1 |
| Valentin, V | 1 |
| Moccetti, T | 1 |
| Chrolavicius, S | 2 |
| Afzal, R | 2 |
| Yusuf, S | 3 |
| Friedewald, VE | 1 |
| Roberts, WC | 1 |
| Little, M | 1 |
| Johnstone, C | 1 |
| Eikelboom, JW | 1 |
| Faxon, DP | 1 |
| Peters, RJ | 1 |
| Watters, M | 1 |
| James, JK | 1 |
| Sacks, DB | 1 |
| Rifai, N | 1 |
| Cannon, CP | 1 |
| Gurfinkel, E | 1 |
| Duronto, E | 1 |
| Colorio, C | 1 |
| Bozovich, G | 1 |
| Mautner, B | 2 |
| Purcell, H | 1 |
| Fox, KM | 1 |
| Weber, S | 1 |
| Laramée, P | 1 |
| Huynh, T | 1 |
| Borzak, S | 1 |
| Diodati, JG | 1 |
| Squire, IB | 1 |
| Deckelbaum, LI | 1 |
| Thornton, AR | 1 |
| Harris, KE | 1 |
| Sax, FL | 1 |
| Lo, MW | 1 |
| Monrad, ES | 1 |
| Galli, M | 1 |
| Santopinto, J | 1 |
| Torres, V | 1 |
| Marcos, E | 1 |
| Pechlaner, C | 1 |
| Gritsch, W | 1 |
| Wiedermann, C | 1 |
| Vila, V | 1 |
| Martínez-Sales, V | 1 |
| Réganon, E | 1 |
| Peris, E | 1 |
| Perez, F | 1 |
| Ruano, M | 1 |
| Aznar, J | 1 |
| Solanki, V | 1 |
| Gaynor, M | 1 |
| Booth, V | 1 |
| MacDonald, R | 1 |
| Freedman, SB | 1 |
| Massel, D | 1 |
| Cruickshank, MK | 1 |
| Becker, RC | 1 |
| Spencer, FA | 1 |
| Gibson, M | 1 |
| Rush, JE | 1 |
| Sanderink, G | 1 |
| Ball, SP | 1 |
| James, S | 1 |
| Armstrong, P | 1 |
| Califf, R | 1 |
| Husted, S | 2 |
| Kontny, F | 2 |
| Niemminen, M | 1 |
| Pfisterer, M | 1 |
| Casserly, IP | 1 |
| Lindahl, B | 3 |
| Lindbäck, J | 1 |
| Jernberg, T | 1 |
| Johnston, N | 2 |
| Stridsberg, M | 1 |
| Venge, P | 2 |
| Mälarstig, A | 1 |
| Siegbahn, A | 3 |
| Menger, MD | 1 |
| Rupec, RA | 1 |
| Boneberger, S | 1 |
| Ruzicka, T | 1 |
| Oldgren, J | 1 |
| Frostfeldt, G | 1 |
| Ahlberg, G | 1 |
| Gustafsson, G | 1 |
| Helmius, G | 1 |
| Nygren, A | 1 |
| Swahn, E | 1 |
| Arnheim, K | 1 |
| Holmes, DR | 1 |
| Kher, A | 1 |
| Megalopoulos, A | 1 |
| Vasiliadis, K | 1 |
| Tsachalis, T | 1 |
| Tsalis, K | 1 |
| Blouhos, K | 1 |
| Alexandridou, S | 1 |
| Betsis, D | 1 |
| Jones, C | 1 |
| Siva, TM | 1 |
| Seymour, FK | 1 |
| O'Reilly, BJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Low Molecular Weight Heparin vs Unfractionated Heparin on Bleeding After Cardiac Surgery[NCT00420667] | 43 participants (Actual) | Interventional | 2004-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for dalteparin and Syndrome
| Article | Year |
|---|---|
Unusual presentation of Lemierre's syndrome: two cases and a review.
Topics: Acenocoumarol; Anti-Bacterial Agents; Anticoagulants; Bacteremia; Deglutition Disorders; Diarrhea; F | 2009 |
Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Clinical Trials as Topic; Dalteparin; Enoxaparin; H | 2000 |
[Low molecular weight heparins in acute coronary syndrome].
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; En | 2001 |
Low-molecular-weight heparin during percutaneous coronary interventions: rationale, results, and recommendations.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Coronary Disease; Enoxapari | 2003 |
The role of enoxaparin in interventional management of patients with acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Blood Coagulation Factors; Cardiac Catheterization; Combined Modality | 2003 |
Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Myoc | 2005 |
Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Enoxaparin; Heparin, Low-Molecular | 2000 |
Enoxaparin in acute coronary syndromes: evidence for superiority over placebo or untreated control.
Topics: Anticoagulants; Aspirin; Confidence Intervals; Coronary Artery Disease; Coronary Thrombosis; Drug Th | 2002 |
[Adverse cutaneous drug reactions].
Topics: Acneiform Eruptions; Dalteparin; Diagnosis, Differential; Drug Eruptions; Eosinophilia; ErbB Recepto | 2007 |
[Long-term administration of Dalteparin in unstable coronary syndrome. FRISC II study opens novel therapeutic perspectives. Fragmin and Fast Revascularization during Instability in Coronary Artery Disease].
Topics: Angina, Unstable; Anticoagulants; Controlled Clinical Trials as Topic; Dalteparin; Death, Sudden, Ca | 2000 |
Implications of the FRISCII trial: initial medical stabilization followed by an early invasive approach is the preferred strategy in unstable coronary syndromes.
Topics: Angina, Unstable; Dalteparin; Electrocardiography; Fibrinolytic Agents; Humans; Injections, Intraven | 2000 |
Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
Topics: Angina, Unstable; Dalteparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Myocardial | 2000 |
Lemierre's syndrome presenting with peritonsillar abscess and VIth cranial nerve palsy.
Topics: Abducens Nerve Diseases; Adolescent; Anti-Bacterial Agents; Cefotaxime; Female; Follow-Up Studies; H | 2006 |
29 trials available for dalteparin and Syndrome
| Article | Year |
|---|---|
[Dysaggregants effect of platelet aggregation in patients with non-ST segment elevation acute coronary syndrome].
Topics: Acute Disease; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Electrocardiography; Female; | 2004 |
Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischa
Topics: Adult; Angina, Unstable; Anticoagulants; Double-Blind Method; Female; Humans; Male; Myocardial Infar | 1999 |
[Enoxaparin failed to show superiority to unfractionated heparin in patients with non ST-elevation acute coronary syndrome in a phase of A to Z trial].
Topics: Acute Disease; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Syndrome; Treatment Fa | 2003 |
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; | 2003 |
The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Drug Therapy, Combi | 2004 |
A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study.
Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Angioplasty, Balloon, Coronary; Angiotensin-Conve | 2004 |
Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: results of the enoxaparin versus tinzaparin (EVET) trial at 6 months.
Topics: Acute Disease; Aged; Angina, Unstable; Electrocardiography; Enoxaparin; Female; Follow-Up Studies; H | 2005 |
[Indirect comparison of changes of parameters of hemostasis during short-term use of ticlopidine and clopidogrel in patients with non-ST elevation acute coronary syndrome].
Topics: Anticoagulants; Aspirin; Clopidogrel; Electrocardiography; Enoxaparin; Fibrinolysis; Fibrinolytic Ag | 2005 |
Using a clinical pathway and education to reduce inappropriate prescribing of enoxaparin in patients with acute coronary syndromes: a controlled study.
Topics: Angina, Unstable; Anticoagulants; Critical Pathways; Drug Utilization; Enoxaparin; Female; Hospitals | 2006 |
Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin
Topics: Angina, Unstable; Anticoagulants; Aspirin; Enoxaparin; Eptifibatide; Female; Heparin; Humans; Male; | 2006 |
A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Drug Therapy, Combin | 2006 |
Switching from Enoxaparin to Bivalirudin in Patients with Acute Coronary Syndromes without ST-segment Elevation who Undergo Percutaneous Coronary Intervention. Results from SWITCH--a multicenter clinical trial.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Enoxaparin; F | 2006 |
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revas
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Blood Transfusion; Coronary Dis | 2006 |
Comparison of effectiveness of enoxaparin versus unfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome.
Topics: Anticoagulants; Electrocardiography, Ambulatory; Enoxaparin; Female; Follow-Up Studies; Heparin; Hum | 2007 |
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Anticoagulants; Coronary Disease; Death, Sudden, Cardiac; | 2007 |
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Cohort Studies; Double-Blind Metho | 2007 |
Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy.
Topics: Aged; Angina, Unstable; Biomarkers; Cause of Death; Enoxaparin; Female; Fibrinolytic Agents; Follow- | 1998 |
Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin.
Topics: Biomarkers; Coronary Disease; Double-Blind Method; Electrocardiography; Enoxaparin; Female; Fibrinol | 1999 |
Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
Topics: Angina, Unstable; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardi | 1999 |
Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Double-Blind Method; Enoxaparin; Female; Heparin; Humans; | 2001 |
Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Aged, 80 and over; Coronary Disease; Enoxaparin; Female; Hemostatics; Heparin; | 2001 |
The SYNERGY trial: study design and rationale.
Topics: Acute Disease; Adult; Aged; Angina, Unstable; Anticoagulants; Coronary Disease; Enoxaparin; Fibrinol | 2002 |
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Anticoagulants; Cohort Studies; Coronary Dis | 2002 |
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy.
Topics: Acute Disease; Aged; Angina, Unstable; Dalteparin; Electrocardiography; Female; Fibrinolytic Agents; | 2005 |
Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Base Sequence; Biomarkers; CD40 Ligand; Coronary Dise | 2006 |
Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
Topics: Acute Disease; Aged; Anticoagulants; Blood Coagulation; Dalteparin; Dose-Response Relationship, Drug | 2008 |
Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II).
Topics: Adult; Aged; Biomarkers; Chemotherapy, Adjuvant; Coronary Angiography; Coronary Circulation; Daltepa | 1999 |
Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
Topics: Angina, Unstable; Dalteparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Myocardial | 2000 |
Improving outcomes in acute coronary syndromes--the FRISC II trial.
Topics: Adult; Angina, Unstable; Anticoagulants; Dalteparin; Female; Humans; Male; Myocardial Infarction; My | 2001 |
34 other studies available for dalteparin and Syndrome
| Article | Year |
|---|---|
[Risk stratification in acute coronary syndrome].
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clin | 2001 |
Cerebral venous thrombosis associated with seat belt syndrome.
Topics: Accidents, Traffic; Child; Diagnosis, Differential; Heparin, Low-Molecular-Weight; Humans; Intracran | 2009 |
Topics: Aged, 80 and over; Anesthesia, Spinal; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Intraoperativ | 2018 |
Purple toes syndrome following stroke thrombolysis and warfarin therapy.
Topics: Acute Kidney Injury; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism, Cholesterol; | 2014 |
Air travel and pulmonary embolism: "economy class syndrome".
Topics: Adult; Aircraft; Anticoagulants; Enoxaparin; Humans; Male; Middle Aged; Pulmonary Embolism; Risk Fac | 2009 |
Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports.
Topics: Acute Disease; Aged; Angina, Unstable; Blood Component Transfusion; Coronary Artery Bypass; Coronary | 2002 |
[Non-ST elevation acute coronary syndrome: changes of parameters of hemostasis during and after treatment with unfractionated heparin and enoxaparin].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Coronary Disease; Enoxaparin; Female; Fibrinolytic Ag | 2003 |
Role of enoxaparin in the invasive management of the ACS patient.
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Disease; Drug Therapy, Combi | 2004 |
Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Coronary Disease; E | 2004 |
Enoxaparin in non-ST segment elevation acute coronary syndromes: duration of therapy is essential to benefit.
Topics: Acute Disease; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Syndrome | 2004 |
Enoxaparin versus heparin: the SYNERGY trial from an emergency medicine perspective.
Topics: Acute Disease; Anticoagulants; Coronary Disease; Emergency Medicine; Enoxaparin; Heparin; Humans; Ra | 2005 |
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Topics: Aged; Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Female; Hemorrhage; Heparin; Hum | 2005 |
Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: insights from the INTERACT trial.
Topics: Acute Disease; Anticoagulants; Arrhythmias, Cardiac; Enoxaparin; Eptifibatide; Heparin; Humans; Myoc | 2005 |
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
Topics: Aged; Anticoagulants; Coronary Disease; Enoxaparin; Female; Hemorrhage; Heparin; Humans; Male; Middl | 2005 |
The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
Topics: Angina, Unstable; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Mal | 2006 |
[Transient left ventricular apical ballooning syndrome--a case report].
Topics: Aged; Amlodipine; Echocardiography, Doppler; Electrocardiography; Enoxaparin; Female; Humans; Simvas | 2007 |
Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Enox | 2007 |
Livedoid vasculopathy and hypercoagulability in a patient with primary Sjögren's syndrome.
Topics: Adult; Anticoagulants; Diagnosis, Differential; Enoxaparin; Female; Humans; Injections, Subcutaneous | 2007 |
Clinical problem-solving. A sinister development--a 35-year-old woman presented to the emergency department with a 2-day history of progressive swelling and pain in her left leg, without antecedent trauma.
Topics: Adult; Anticoagulants; Constriction, Pathologic; Contraceptives, Oral; Edema; Enoxaparin; Female; Fi | 2007 |
The Editor's Roundtable: arterial thrombosis and acute coronary syndromes.
Topics: Administration, Cutaneous; Angina, Unstable; Anticoagulants; Cardiac Catheterization; Comorbidity; C | 2007 |
Guidelines for the management of acute coronary syndromes 2006.
Topics: Aged; Australia; Coronary Disease; Enoxaparin; Humans; Practice Guidelines as Topic; Syndrome | 2007 |
Enoxaparin (Clexane) HITS.
Topics: Antibodies; Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Platelet Aggr | 1996 |
Enoxaparin (Clexane) HITS.
Topics: Anticoagulants; Blood Loss, Surgical; Enoxaparin; Female; Humans; Knee Prosthesis; Middle Aged; Post | 1996 |
Improving outcome in acute coronary syndromes - as good as it gets?
Topics: Angina, Unstable; Anticoagulants; Dalteparin; Enoxaparin; Humans; Myocardial Infarction; Platelet Gl | 1999 |
[The treatment of acute coronary syndromes of the "non-ST elevation" type with enoxaparin: the TIMI 11B study. Thrombolysis in Myocardial Infarct].
Topics: Acute Disease; Coronary Disease; Double-Blind Method; Electrocardiography; Enoxaparin; Fibrinolytic | 2000 |
Enoxaparin for acute coronary syndromes?
Topics: Acute Disease; Enoxaparin; Fibrinolytic Agents; Humans; Myocardial Ischemia; Syndrome | 2001 |
Superiority of enoxaparin over unfractionated heparin for the treatment of acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Coronary Disease; Enoxaparin; Heparin; Humans; Syndrome | 2002 |
Optimal strategy for administering enoxaparin to patients undergoing coronary angiography without angioplasty for acute coronary syndromes.
Topics: Acute Disease; Aged; Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Disease | 2002 |
Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes.
Topics: Age Factors; Aged; Angina, Unstable; Area Under Curve; Aspirin; Biomarkers; Body Weight; Coronary Ar | 2002 |
The primacy of clinical effectiveness for cost effectiveness analysis.
Topics: Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Dalteparin; Fibrinolytic Agents; | 2003 |
Dalteparin: only protective in hepatic ischemia-reperfusion or also capable of preventing injury in liver hyperperfusion syndrome?
Topics: Animals; Anticoagulants; Dalteparin; Fibrinolytic Agents; Liver; Liver Diseases; Rats; Reperfusion I | 2006 |
New trials of LMW heparins - light and heavy weight as good on short but what about longer distances?
Topics: Angina, Unstable; Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Myocardial Infa | 1999 |
Acute coronary syndromes: extending medical intervention for five days before proceeding to revascularization.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Coronary Art | 2000 |
Recurrent arterial thromboses in a woman with heparin induced thrombocytopenia, successfully managed with iloprost followed by clopidogrel. An alternative therapeutic option for heparin induced thrombocytopenia type II syndrome.
Topics: Aged; Arterial Occlusive Diseases; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agen | 2006 |